Travere insider plans sale of 100,087 TVTX shares

Travere Therapeutics insider plans additional share sale under Rule 144.

Accepted by SEC EDGAR 02/03/2026 - 11:38 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics insider plans additional share sale under Rule 144. A person identified as Eric M. Dube has filed to sell 100,087 shares of common stock of Travere Therapeutics through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 02/03/2026 and an aggregate market value of $3,289,859.69. The filing notes 89,472,327 common shares outstanding.

The 100,087 shares were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 02/02/2026. Over the prior three months, the same seller completed two sales of Travere common stock totaling 8,135 and 51,865 shares, generating gross proceeds of $244,153.28 and $1,560,982.50.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for TVTX disclose about upcoming share sales?

The Form 144 indicates a planned sale of 100,087 Travere Therapeutics common shares. These are to be sold on NASDAQ through Fidelity, with an approximate sale date of 02/03/2026 and an aggregate market value of $3,289,859.69 based on the filing’s figures.

How many Travere Therapeutics (TVTX) shares are covered by this Form 144?

The notice covers 100,087 common shares of Travere Therapeutics. These shares are listed with an aggregate market value of $3,289,859.69 and will be sold on NASDAQ. The filing also states there were 89,472,327 common shares outstanding at the time referenced.

Who is the selling security holder in the Travere Therapeutics (TVTX) Form 144?

The selling security holder is identified as Eric M. Dube. The filing lists his address in San Diego, California and shows he is selling Travere Therapeutics common stock through Fidelity Brokerage Services on NASDAQ under Rule 144 requirements.

How were the Travere Therapeutics (TVTX) shares in this Form 144 acquired?

The 100,087 shares were acquired on 02/02/2026 via restricted stock vesting. The issuer granted the shares as compensation, with the acquisition and payment dates both listed as 02/02/2026, indicating a non-cash compensation-based award rather than an open-market purchase.

What prior Travere Therapeutics (TVTX) share sales has the filer reported in the last three months?

The filer reports two prior sales in the last three months. On 01/23/2026, 8,135 common shares were sold for gross proceeds of $244,153.28, and on 01/27/2026, 51,865 common shares were sold for gross proceeds of $1,560,982.50.

On which exchange will the Travere Therapeutics (TVTX) shares in this Form 144 be sold?

The filing states that the 100,087 Travere Therapeutics common shares are to be sold on NASDAQ. Fidelity Brokerage Services LLC is listed as the broker, and the approximate date of sale is given as 02/03/2026 under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001763494
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Travere Therapeutics, Inc.
SEC File Number	001-36257
Address of Issuer	3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CALIFORNIA 92130
Phone	888-969-7879
Name of Person for Whose Account the Securities are To Be Sold	Dube Eric M
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	100087	3289859.69	89472327	02/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/02/2026	Restricted Stock Vesting	Issuer			100087	02/02/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric M. Dube 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	01/23/2026	8135	244153.28
Eric M. Dube 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	01/27/2026	51865	1560982.50

144: Remarks and Signature

Remarks
Date of Notice	02/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jared Cook, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Eric M. Dube
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)